

Bioinformatics analysis of a long non-coding RNA and mRNA regulation network in rats with middle cerebral artery occlusion based on RNA sequencing

XIANCHUN DUAN^{1,3}, LAN HAN^{2,3}, DAIYIN PENG^{2,3}, CAN PENG^{2,3},
LING XIAO⁴, QIUYU BAO⁴ and HUASHENG PENG^{2,3}

¹Department of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230031; ²School of Pharmacy, ³Key Laboratory of Chinese Medicinal Formula Research, Anhui University of Chinese Medicine, Hefei, Anhui 230012; ⁴School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, P.R. China

Received July 31, 2018; Accepted March 7, 2019

DOI: 10.3892/mmr.2019.10300

Abstract. Long non-coding RNAs (lncRNAs) have been proven to be critical gene regulators of development and disease. The main aim of the present study was to elucidate the lncRNA-mRNA regulation network in ischemic stroke induced by middle cerebral artery occlusion (MCAO) using RNA sequencing (RNA-seq) in rats. lncRNA expression profiles were screened in brain tissues to identify a number of differentially expressed lncRNAs (DELs) and genes (DEGs) by RNA-seq. Reverse transcription-quantitative polymerase chain reaction was performed to further confirm the lncRNA expression data. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were used to mine mRNA functions, and a lncRNA-mRNA network was constructed. Additionally, *cis*- and *trans*-regulatory gene analyses of DELs were predicted. A total of 134 DELs (fold change >2, false discovery rate <0.05) and 1,006 DEGs (fold change >2 and P<0.05) were identified. Eighteen lncRNAs were predicted to regulate heme oxygenase 1, mitotic checkpoint serine/threonine kinase B, chemokine ligand 2 and DNA Topoisomerase II α , amongst other genes. These genes are all associated with a cellular response to inorganic substances, alkaloids, estradiol, reactive oxygen species, metal ions, oxidative stress, and are associated with metabolic pathways, chemokine signaling pathways, malaria, Parkinson's disease, the cell cycle and other GO and KEGG pathway enrichments. The present study identifies novel DELs and an lncRNA-mRNA regulatory network that

may allow for an improved understanding of the molecular mechanism of ischemic stroke induced by MCAO.

Introduction

Stroke, universally acknowledged as a cerebrovascular accident, may result in lasting brain damage, long-term disability or even mortality (1,2). A multitude of biological processes are implicated in ischemic stroke, including oxygen deprivation, neuronal necrosis and an intense inflammatory response (3,4). MicroRNAs (miRNAs), long non-coding RNAs (lncRNAs) and even circular RNAs (circRNAs) contribute to RNA-mediated networks (5-8) that regulate notable cellular events through a variety of complicated mechanisms (9,10). These networks have been implicated in ischemic stroke in previous studies (5-10); however, there remain gaps in current knowledge in this regard, and novel ncRNAs need be mined in order to provide a better understanding of the precise molecular mechanisms involved in ischemic stroke.

lncRNAs have been proven to be critical gene regulators of development and disease (11-13). lncRNAs may also perform functions through competitively binding to miRNAs known as competitive endogenous RNAs (14). Washietl *et al* (15) systematically analyzed the conservatism of human lncRNA and other six mammalian lncRNA and identified that ~54% human lncRNA loci may be mapped to that of a rat. A previous study has demonstrated that significantly differentially expressed lncRNAs (DELs) may contribute to the stabilization of mRNA expressions in stroke (7). Stroke-induced lncRNAs may also interact with chromatin-modifying proteins and modulate genes associated with ischemic brain damage (16,17). Furthermore, lncRNA BC088414 was revealed to be involved with apoptosis-associated genes following hypoxic-ischemic brain damage (8). Similarly, another study suggested that lncRNA C2dat1 may modulate calcium/calmodulin-dependent protein kinase II expression to promote neuronal survival following cerebral ischemia (10). Although a host of lncRNAs have been identified by massive parallel sequencing, to date, little

Correspondence to: Professor Daiyin Peng, School of Pharmacy, Anhui University of Chinese Medicine, 1 Qianjiang Road, Hefei, Anhui 230012, P.R. China
E-mail: pengdaiyin@163.com

Key words: middle cerebral artery occlusion, long non-coding RNA

is known on functional RNA molecules and RNA-mediated regulation networks in ischemic stroke.

The main aim of the present study is to elucidate the lncRNA-mRNA regulation networks in ischemic stroke induced by middle cerebral artery occlusion (MCAO) using RNA sequencing (RNA-seq) in rats.

Materials and methods

MCAO model and tissue preparation. A focal cerebral ischemia model induced by MCAO, prepared as previously described (18), was prepared using 20 7-week-old male Sprague-Dawley rats of a specific pathogen-free grade (weighing 200±20 g), purchased from the experimental animal center of Anhui Medical University (Anhui, China). The study protocol was ethically approved by the Committee on the Ethics of Animal Experiments of Anhui University of Chinese Medicine (approval no. 2012AH-036-03). In brief, the animals were fasted overnight but allowed *ad libitum* access to water. They were then anesthetized with chloral hydrate (350 mg/kg, intraperitoneal injection). A 4-0 silicon-coated monofilament nylon suture with a round tip was inserted through an arteriotomy in the common carotid artery just below the carotid bifurcation and then advanced into the internal carotid artery ~18 mm distal to the carotid bifurcation until a mild resistance was felt. Following 2 h of MCAO, the filament was removed to allow reperfusion. As a control, control-operated rats underwent identical surgery but did not have the suture inserted. Four days subsequent to MCAO, the left hemispheres were collected and immediately frozen in liquid nitrogen.

RNA-seq. RNA-seq was performed by Ao-Ji Bio-Tech (Shanghai, China). Briefly, total RNA was extracted using an RNeasy Mini kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's protocol. The RNA quality control was performed using Nanodrop 2000 and Agilent 2100, and mainly depended on the concentration, purity and integrity of the RNA. Ribosomal RNA was removed from total RNA using Ribo-Zero rRNA removal beads (Illumina, Inc., San Diego, CA, USA). Libraries were constructed according to the standard TruSeq protocol (19). Purified cDNA libraries were prepared for cluster generation and sequencing on an Illumina HiSeq 2500 (Illumina, Inc.) according to the manufacturer's protocol. Subsequently, data analyses were performed *in silico*.

lncRNA annotation. Quality control of the RNA-Seq reads was conducted using FastQC (v0.11.3) (The Babraham Institute, Cambridge, UK). Reads were trimmed using the software seqtk (github.com/lh3/seqtk) for known Illumina TruSeq adapter sequences, poor reads and ribosome RNA reads. Trimmed reads were aligned to the rat genome (Rn6) using Hisat2 (version 2.0.4) (20). Transcripts were assembled using Stringtie (v1.3.0) (20,21). Transcripts constructed from Stringtie were compiled together by gffcompare (v0.9.8) (20,21). Transcripts detected in at least five samples (half of the total number) were considered to be bona fide transcripts. Transcripts, with the exception of those with just one exon and shorter than 200 base pairs, were further analyzed for the identification of lncRNAs. Transcripts with class codes 'i,' 'u,' and 'x,' were considered to be potential novel long transcripts.

Pfam (22), Coding Potential Calculator (CPC) (23) and Coding-Non-Coding Index (CNCI) (24) were used to estimate the coding potential of each novel transcript. Transcripts with a Pfam score <0, CNCI <0 and CPC non-significant were considered to lack coding potential. Transcripts were compared with annotation databases, including NONCODE (v4) (<http://www.noncode.org>) and Ensembl (25). The matched transcripts were considered to be known lncRNAs, and others were considered to be novel lncRNAs. All lncRNAs were quantified using Stringtie. According to the positional association between lncRNA and mRNA in the genome, lncRNA may be classified into six types: Bidirectional, exonic_antisense, exonic_sense, intergenic, intronic_antisense and intronic_sense (26).

The lncRNA-mRNA coexpression network. Initially, the DELs and differentially expressed genes (DEGs) were analyzed using EdgeR (27). For DEGs, \log_2 [fold change (FC)] >1 and $P < 0.05$ were used as the cutoff values. Meanwhile, \log_2 (FC) >1 and false discovery rate (FDR) <0.05 were used as the threshold for DELs. Hierarchical clustering of DELs was performed based on mean signals using a Euclidean distance function. In addition, a volcano plot was generated. The Pearson's correlation coefficient (PCC) between lncRNAs and mRNAs was calculated (cutoff value, $PCC > 0.9$, $P < 0.05$) and the lncRNA-mRNA regulatory network was structured using Cytoscape 2.8.3 (28).

Prediction of target genes and enrichment analysis. *cis*- or *trans*-acting algorithms were used to predict the potential targets of lncRNAs. The first algorithm predicted potential target genes of *cis*-acting lncRNAs that were physically located within 10 kb upstream or 20 kb downstream of lncRNAs using liftOver genome browser (genome.ucsc.edu/cgi-bin/hgLiftOver). The second algorithm predicted potential target genes of *trans*-acting lncRNAs based on the lncRNA-mRNA complementary sequences, and predicted lncRNA-mRNA duplex energy. First, BLASTN (29) was performed to detect potential target mRNA sequences with >95% identity and E value < 1×10^{-5} (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). Then, RNAplex (30) was used to calculate the complementary energy between lncRNAs and their potential *trans*-regulated target genes with RNAplex-10⁻³⁰. Gene Ontology (GO) (31) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (32) enrichment analyses of the identified potential target genes were performed using the Database for Annotation, Visualization and Integrated Discovery (33); and $P < 0.05$ was considered to indicate a statistically significant difference.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from left hemisphere samples using TRIzol[®] reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and reverse-transcribed using a Thermo Fisher Scientific RevertAid First Strand cDNA Synthesis kit (cat. no. K1622; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol at 42°C for 60 min. To further confirm the expression data from RNA-seq, a cutoff value (FC >2, $P < 0.05$) was randomly selected for qPCR verification. The expression levels of six randomly DELs (NONRATT027551.2, MSTRG.1836.1, MSTRG.4344.10,

Table I. Primer sequences.

Gene	Sequence	Polymerase chain reaction product length (base pairs)
GAPDH	F: 5'-CCTGGTATGACAACGAATTTG-3' R: 5'-CAGTGAGGGTCTCTCTCTTCC-3'	131
NONRATT027551.2	F: 5'- GGACCTGGAAGGTGAACAGG-3' R: 5'-TGAATGGGTGACCAACAGGG-3'	118
MSTRG.1836.1	F: 5'-CCATTGTCCTTCCATCCCCC-3' R: 5'-CCACCCTACCAAACCTTCCCC-3'	85
MSTRG.4344.10	F: 5'-GACTTAGGCACAGTGGGTGG-3' R: 5'-ATGGCAGAGAGCGAATGGAG-3'	119
MSTRG.7720.11	F: 5'-TCCCTAGAGCAGTCCTCACC-3' R: 5'- ATCTCGGGTTCGCCCTTTTGT-3'	97
NONRATT005132.2	F: 5'-CCTGACTATGGCACGTCCTC-3' R: 5'-CTGAGTCCAGTGTGCCTGTT-3'	152
MSTRG.20633.3	F: 5'-CTTTCACCTCCGAGAACCCCC-3' R: 5'-GCAAGCAGGTTGGTTCCTTG-3'	117

F, forward; R, reverse.

Table II. Results of the RNA sequencing.

Sample ID	Raw reads	Clean reads	Clean ratio (%)	rRNA trimmed	Mapped reads	Mapped ratio
MCAO 1	155190870	147282901	94.90	147214274	131290423	0.824026529
MCAO 2	144450130	136930064	94.79	136768708	120311195	0.812346697
MCAO 3	151411986	142862439	94.35	142724911	125540743	0.804354762
Control 1	169303916	160544960	94.83	160466568	142289885	0.819832697
Control 2	136533930	129672892	94.97	129609605	116072061	0.828973282
Control 3	124878376	118432971	94.84	118349299	105506286	0.821661742

MCAO, middle cerebral artery occlusion.

MSTRG.7720.11, NONRATT005132.2 and MSTRG.20633.3) were assayed using a SYBRGreen flurophore (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the PikoReal real-time PCR system (Thermo Fisher Scientific, Inc.) under the following conditions: Initial denaturation at 95°C for 30 sec, followed by 40 cycles at 95°C for 30 sec and 60°C for 30 sec, and a final extension step at 4°C for 20 min. FC was determined using the $2^{-\Delta\Delta C_q}$ method (34). GAPDH mRNA was used as an internal control. The primers used are listed in Table I.

Statistical analysis. The comparisons between the MCAO group and the control group were determined using a Student's t-test for the RT-qPCR results by SPSS 22.0 statistical software (IBM Corp., Armonk, NY, USA). $P < 0.05$ was considered to indicate a statistically significant difference. The PCC between lncRNAs and mRNAs was calculated using the Hmisc package in R based on the expression determined using RNA-seq ($PCC > 0.9$, $P < 0.05$). The correlation analysis

between the RT-qPCR results and RNA-seq results was calculated in Excel 2013 (Microsoft Corporation, Redmond, WA, USA) with the function of CORR.

Results

lncRNA-sequencing data analysis. The present study characterized the lncRNA landscape and expression by performing deep RNA-seq experiments on three control and three MCAO tissue samples. Subsequent to the seqtk quality assessment of sequencing, >33 million total original reads for each sample were obtained, and the proportion of bases with quality values >20 was >94%. These results indicated that the quality of the sequencing results was acceptable (Table II). Subsequent to filtering out the adaptor sequence and low quality reads, the percentage of clean reads within the raw reads accounted for 94% of the total sequences in two groups. Hisat2 software was used to map the obtained clean reads to the *Rattus norvegicus* reference genome. As presented in Table II, ~97% of the




Figure 1. Class type and chromosome distribution of lncRNAs identified in the control and MCAO group. (A) Venn diagram of lncRNA in the control and MCAO groups. (B) According to the positional association between lncRNA and mRNA in the genome, lncRNAs may be classified into six types: Bidirectional, exonic antisense, exonic sense, intergenic, intronic antisense and intronic sense. (C) Number of lncRNAs on each chromosome in the MCAO and control groups. MCAO, Middle cerebral artery occlusion; lncRNA, long noncoding RNA.

trimmed reads were mapped onto the reference genome. In total, 24,304 lncRNAs were screened from six samples, and there were 23,255 shared lncRNAs detected in the MCAO and control groups (Fig. 1A). The majority of the identified lncRNAs were transcribed from protein-coding exons; others were from introns and intergenic regions (Fig. 1B). In addition, the present study analyzed the distribution of the identified lncRNAs on the rat chromosomes; 24,304 lncRNA transcripts were identified in all chromosomes, and chromosome 1 included the most lncRNAs (Fig. 1C).

Identification of DEGs and DELs. EdgeR was used to filter DEGs and DELs and differentiate their expression between the control and MCAO groups. A total of 1,007 DEGs ($|\text{FC}| > 2$, $P < 0.05$) were identified, including 785 upregulated genes and 222 downregulated genes. Similarly, as presented in Fig. 2, 134 DELs ($|\text{FC}| > 2$, $\text{FDR} < 0.05$) were identified in

the MCAO group (Fig. 2A and B), including 77 upregulated and 57 downregulated DELs (Fig. 2C and D). In the present study, it was revealed that the FC values of certain DELs were equal to positive infinity and negative infinity, meaning that these lncRNAs are switched-on or off with MCAO. Essentially, positive or negative infinity indicates zero expression of the lncRNA in normal or MCAO groups. It was speculated that this may be associated with the abundance of lncRNAs and the sensitivity to RNA-seq. The top five upregulated DELs were NONRATT027551.2, MSTRG.1836.1, MSTRG.4344.10, NONRATT028102.2 and MSTRG.31500.2; the top five downregulated DELs were MSTRG.7720.11, NONRATT005132.2, MSTRG.20633.3, NONRATT020232.2 and MSTRG.1836.3.

lncRNA-mRNA network. The cutoff correlation r -values ($|\text{IPCC}| > 0.9$) and P -values ($P < 0.05$) were selected to structure





Figure 2. RNA-seq data on the differentially expressed lncRNAs between the model and control groups. (A) Hierarchical cluster of DEIs between the MCAO and control groups. The color code in each heat map is linear, with green indicating the least and red indicating the greatest differentiation. The mean signals of the altered lncRNAs in each of the two groups were clustered using a Euclidean distance function. The lncRNAs with the most similar expression patterns were placed next to each other ($n=3$ per group). (B) A volcano plot of the RNA-seq FC and P-value of MCAO group compared with the control group. Blue and red points stand for DEIs. Gray points represent lncRNAs which are not differentially expressed. (C) Upregulated and (D) downregulated DEIs as exhibited in the red and blue boxes, respectively, represent the results. MCAO, Middle cerebral artery occlusion; lncRNA, long noncoding RNA; RNA-seq, RNA sequencing; FC, fold change; DEI, differentially expressed lncRNAs.

a lncRNA-mRNA co-expression network between DEGs and DEIs. As Fig. 3 presents, 46 DEGs, 104 DEIs and 664 edges were filtered out using Cytoscape to construct the co-expression network. The co-expression-associated top 30 GO terms and pathway terms enrichment analyses presented in Figs. 4 and 5 suggest that these DEIs were associated with the cellular response to inorganic substances, alkaloids, estradiols, reactive oxygen species, metal ions and oxidative stress. In particular, the heme oxygenase 1 (HO-1) gene participates in many of these functions. A multitude of pathways were implicated, including metabolic pathways, chemokine signaling pathways, malaria, Parkinson's disease and the cell cycle. Notably, the BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) and C-C motif chemokine ligand 2 (CCL2) genes were associated with the cell cycle.

Regulatory analysis of DEIs. A total of 91 *cis*-regulatory genes of 94 DEIs, including 55 upregulated lncRNAs in the MCAO group were identified; 14 of the 91 *cis*-regulatory genes exhibited differential expression. A total of 13 of the DEI/*cis*-regulatory gene pairs had positive correlations as follows: NONRATT021925.2 (Rho GDP dissociation inhibitor β), NONRATT004791.2 (G protein subunit γ transducing 2), NONRATT015286.2 (perioctin), MSTRG.30235.10 (LRR binding FLII interacting protein 1), NONRATT015403.2 (IQ motif containing GTPase activating protein 3), NONRATT008267.2 (kinesin family member 14), NONRATT009960.2 (non-SMC condensin I complex subunit G), NONRATT011312.2 (retinol binding protein 3), NONRATT005985.2 (DNA topoisomerase II α), NONRATT016680.2 (ENSRNOG00000053081), NONRATT013960.2 (galanin receptor 1), NONRATT016022.2



NONRATT005132.2 and MSTRG.20633.3 were significantly downregulated in the MCAO group compared with the control ($P<0.01$), also consistent with the RNA-seq data. These results, revealing that the RNA-seq results were consistent with the RT-qPCR results, verified that the RNA-seq results were reliable (Fig. 6).

A host of lncRNAs have been indicated to be involved in ischemic stroke by microarray or RNA-seq studies (35,36).




Figure 4. Top 30 significant enrichment of GO terms in the long noncoding RNA-mRNA network. GO, gene ontology; ERK, extracellular regulated kinase.




Figure 5. Top 30 significant enrichment of KEGG pathway terms in the long noncoding RNA-mRNA network. KEGG, Kyoto Encyclopedia of Genes and Genomes; TNF, tumor necrosis factor; HIF-1, hypoxia-inducible factor 1; ECM, extracellular matrix.

Table III. Differentially expressed lncRNAs mechanisms involved in *cis*-regulatory elements.

lncRNA ID	log2FC	Q value	Up/downregulated	Type	Gene ID	Gene name	log2FC	P-value	Up/downregulated
NONRATT017723.2	-3.68	0.0125	Down	<i>cis</i>	ENSRNOG000000000633	Rhobtb1	0.85	0.1148	-
NONRATT008064.2	-6.73	0.0145	Down	<i>cis</i>	ENSRNOG000000001183	Hnfla	1.25	0.7907	-
NONRATT000377.2	+∞	0.0492	Up	<i>cis</i>	ENSRNOG000000001492	Slc8a2	0.13	0.9091	-
NONRATT006957.2	6.69	0.0000	Up	<i>cis</i>	ENSRNOG000000001982	Cblb	0.60	0.1402	-
NONRATT009831.2	-5.72	0.0425	Down	<i>cis</i>	ENSRNOG000000002137	Aasdh	0.21	0.7048	-
NONRATT009718.2	-5.48	0.0020	Down	<i>cis</i>	ENSRNOG000000002146	Pkd2	0.29	0.5035	-
NONRATT009780.2	-3.94	0.0473	Down	<i>cis</i>	ENSRNOG000000002208	Shroom3	0.83	0.1301	-
NONRATT005026.2	6.14	0.0000	Up	<i>cis</i>	ENSRNOG000000002607	Sox9	0.25	0.5566	-
NONRATT014565.2	-2.91	0.0492	Down	<i>cis</i>	ENSRNOG000000002864	Nacc1	0.26	0.5744	-
NONRATT005048.2	-∞	0.0432	Down	<i>cis</i>	ENSRNOG000000003144	Gprc5c	0.48	0.5195	-
NONRATT024547.2	-∞	0.0082	Down	<i>cis</i>	ENSRNOG000000003955	Spat7	0.26	0.6325	-
NONRATT026753.2	3.08	0.0450	Up	<i>cis</i>	ENSRNOG000000003993	Thap2	0.26	0.7629	-
NONRATT005132.2	-8.71	0.0471	Down	<i>cis</i>	ENSRNOG000000004049	Baiap2	-0.04	0.8211	-
NONRATT026300.2	+∞	0.0469	Up	<i>cis</i>	ENSRNOG000000004628	Dazap2	0.13	0.8554	-
NONRATT026156.2	7.44	0.0000	Up	<i>cis</i>	ENSRNOG000000005332	Csdc2	-0.58	0.1263	-
NONRATT005775.2	3.69	0.0453	Up	<i>cis</i>	ENSRNOG000000005538	Psmc11	-0.03	0.7616	-
NONRATT023334.2	-4.85	0.0448	Down	<i>cis</i>	ENSRNOG000000005711	Ptprd	-0.21	0.4658	-
NONRATT021925.2	+∞	0.0000	Up	<i>cis</i>	ENSRNOG000000005809	Arhgdib	1.81	0.0074	Up
NONRATT004791.2	4.02	0.0218	Up	<i>cis</i>	ENSRNOG000000006108	Gngt2	4.95	0.0000	Up
MSTRG.22811.4	-∞	0.0388	Down	<i>cis</i>	ENSRNOG000000006966	Nfia	0.21	0.6590	-
NONRATT025479.2	-4.14	0.0000	Down	<i>cis</i>	ENSRNOG000000007610	Gdf11	0.08	0.9402	-
NONRATT020232.2	-7.72	0.0000	Down	<i>cis</i>	ENSRNOG000000007804	C1galt1	0.45	0.2729	-
NONRATT008198.2	4.83	0.0305	Up	<i>cis</i>	ENSRNOG000000007887	Elk4	0.76	0.2762	-
NONRATT022252.2	+∞	0.0305	Up	<i>cis</i>	ENSRNOG000000008099	Galnt12	0.85	0.2496	-
NONRATT024954.2	-3.98	0.0471	Down	<i>cis</i>	ENSRNOG000000008155	Dus4l	-0.17	0.7340	-
NONRATT028439.2	5.06	0.0430	Up	<i>cis</i>	ENSRNOG000000008187	Ubash3b	-0.21	0.4764	-
NONRATT022210.2	-4.24	0.0492	Down	<i>cis</i>	ENSRNOG000000008237	Unc13b	0.30	0.6027	-
NONRATT027551.2	9.08	0.0119	Up	<i>cis</i>	ENSRNOG000000008709	Arhgap32	-0.24	0.5090	-
NONRATT027576.2	-∞	0.0061	Down	<i>cis</i>	ENSRNOG000000008757	Tmem218	0.16	0.8511	-
NONRATT021402.2	-∞	0.0291	Down	<i>cis</i>	ENSRNOG000000009156	Tra2a	0.47	0.2267	-
NONRATT021972.2	+∞	0.0335	Up	<i>cis</i>	ENSRNOG000000009338	Kras	-0.11	0.6201	-
NONRATT022345.2	-5.23	0.0000	Down	<i>cis</i>	ENSRNOG000000009795	Nfib	0.04	0.9239	-
MSTRG.16900.3	-4.70	0.0248	Down	<i>cis</i>	ENSRNOG000000009882	Ppp3ca	0.07	1.0000	-
MSTRG.19870.10	+∞	0.0000	Up	<i>cis</i>	ENSRNOG00000010993	Dpm1	-0.14	0.5966	-
NONRATT008272.2	-3.96	0.0431	Down	<i>cis</i>	ENSRNOG00000011063	Dennd1b	0.20	0.7240	-
MSTRG.10245.2	6.31	0.0002	Up	<i>cis</i>	ENSRNOG00000011704	Fbxo34	-0.37	0.2745	-

Table III. Continued.

lncRNA ID	log2FC	Q value	Up/downregulated	Type	Gene ID	Gene name	log2FC	P-value	Up/downregulated
NONRATT001841.2	3.41	0.0430	Up	cis	ENSRNOG000000012110	Col17a1	-1.52	0.0483	Down
NONRATT002035.2	7.89	0.0003	Up	cis	ENSRNOG000000012324	Soga3	-0.04	0.7913	-
MSTRG.22390.2	-∞	0.0000	Down	cis	ENSRNOG000000012634	Fbxo10	-0.41	0.1989	-
MSTRG.22390.1	+∞	0.0000	Up	cis	ENSRNOG000000012634	Fbxo10	-0.41	0.1989	-
NONRATT015286.2	5.30	0.0425	Up	cis	ENSRNOG000000012660	Postn	3.66	0.0004	Up
MSTRG.1836.3	-7.60	0.0041	Down	cis	ENSRNOG000000012716	Chd2	0.06	0.9929	-
MSTRG.1836.1	9.24	0.0001	Up	cis	ENSRNOG000000012716	Chd2	0.06	0.9929	-
NONRATT016334.2	+∞	0.0000	Up	cis	ENSRNOG000000012734	Deun1d1	-0.20	0.5140	-
NONRATT015057.2	-4.70	0.0049	Down	cis	ENSRNOG000000012799	Prkaa1	-0.28	0.3193	-
NONRATT000212.2	-6.12	0.0378	Down	cis	ENSRNOG000000013194	Rps6ka2	-0.14	0.5704	-
NONRATT030198.2	5.34	0.0000	Up	cis	ENSRNOG000000013213	Epha4	0.35	0.5640	-
NONRATT010352.2	-6.23	0.0004	Down	cis	ENSRNOG000000013353	Tmem260	0.07	0.9952	-
NONRATT029471.2	4.91	0.0082	Up	cis	ENSRNOG000000013557	Lanc1	-0.17	0.5373	-
NONRATT028588.2	6.05	0.0378	Up	cis	ENSRNOG000000013829	Chrna3	1.17	0.2523	-
NONRATT023203.2	+∞	0.0007	Up	cis	ENSRNOG000000013956	Rnf38	0.17	0.7841	-
MSTRG.29693.5	+∞	0.0484	Up	cis	ENSRNOG000000013991	Creg2	-0.69	0.2339	-
MSTRG.12408.2	-∞	0.0041	Down	cis	ENSRNOG000000014007	Gfod1	0.04	0.9704	-
NONRATT004566.2	3.44	0.0440	Up	cis	ENSRNOG000000015002	Abhd15	0.76	0.3266	-
MSTRG.15067.2	+∞	0.0090	Up	cis	ENSRNOG000000015334	Fcho2	0.49	0.2280	-
NONRATT003289.2	7.56	0.0052	Up	cis	ENSRNOG000000015717	Ptpre	0.21	0.6977	-
NONRATT013960.2	-3.81	0.0248	Down	cis	ENSRNOG000000016654	Galr1	-3.38	0.0001	Down
NONRATT028604.2	4.71	0.0000	Up	cis	ENSRNOG000000017193	Lingo1	-0.52	0.2454	-
NONRATT016022.2	-5.74	0.0001	Down	cis	ENSRNOG000000017712	Cartpt	-3.83	0.0001	Down
NONRATT015604.2	-5.60	0.0000	Down	cis	ENSRNOG000000018166	Prkab2	0.00	0.8495	-
NONRATT024616.2	-3.79	0.0143	Down	cis	ENSRNOG000000019584	Dlk1	-4.21	0.0000	Down
MSTRG.30235.10	8.50	0.0275	Up	cis	ENSRNOG000000019892	Lrrfip1	1.14	0.0479	Up
NONRATT026461.2	+∞	0.0118	Up	cis	ENSRNOG000000020230	Pias4	0.17	0.8050	-
NONRATT018820.2	-∞	0.0002	Down	cis	ENSRNOG000000020337	Sla2	0.52	0.5953	-
NONRATT004912.2	6.00	0.0041	Up	cis	ENSRNOG000000020658	Aarsd1	0.05	0.9927	-
NONRATT019712.2	-6.20	0.0446	Down	cis	ENSRNOG000000021262	Slc23a2	0.09	0.9742	-
NONRATT027268.2	5.27	0.0071	Up	cis	ENSRNOG000000022570	Pus7l	0.51	0.5096	-
MSTRG.12863.69	+∞	0.0304	Up	cis	ENSRNOG000000023661	Celf2	0.30	0.5495	-
NONRATT030368.2	5.55	0.0043	Up	cis	ENSRNOG000000025527	Mtcl1	0.16	0.8136	-
NONRATT027862.2	-3.75	0.0304	Down	cis	ENSRNOG000000027145	Rora	-0.16	0.5963	-
NONRATT015403.2	4.83	0.0409	Up	cis	ENSRNOG000000027894	Iqgap3	2.03	0.0137	Up
NONRATT003576.2	+∞	0.0028	Up	cis	ENSRNOG000000028017	Tmem109	0.36	0.4097	-

Table III. Continued.

lncRNA ID	log2FC	Q value	Up/downregulated	Type	Gene ID	Gene name	log2FC	P-value	Up/downregulated
NONRATT004361.2	-5.86	0.0409	Down	<i>cis</i>	ENSRNOG000000028341	Alkbh5	0.00	0.8591	-
NONRATT012903.2	-5.26	0.0000	Down	<i>cis</i>	ENSRNOG000000031706	AABR07027388.1	-0.85	0.1761	-
MSTRG.15111.2	+∞	0.0000	Up	<i>cis</i>	ENSRNOG000000032735	Srek1	0.18	0.7203	-
MSTRG.15111.1	-7.42	0.0000	Down	<i>cis</i>	ENSRNOG000000032735	Srek1	0.18	0.7203	-
NONRATT028102.2	10.21	0.0000	Up	<i>cis</i>	ENSRNOG000000033809	Mlh1	0.76	0.1272	-
NONRATT019889.2	-4.60	0.0113	Down	<i>cis</i>	ENSRNOG000000034031	Vstm2l	-0.45	0.3771	-
NONRATT008267.2	+∞	0.0039	Up	<i>cis</i>	ENSRNOG000000037211	Kif14	5.80	0.0005	Up
NONRATT009960.2	4.06	0.0430	Up	<i>cis</i>	ENSRNOG000000038572	Ncapg	3.28	0.0054	Up
MSTRG.21884.7	+∞	0.0492	Up	<i>cis</i>	ENSRNOG000000042458	Stau2	-0.20	0.5104	-
NONRATT030464.2	5.30	0.0042	Up	<i>cis</i>	ENSRNOG000000046053	Nudt10	-0.59	0.1573	-
MSTRG.15418.3	+∞	0.0448	Up	<i>cis</i>	ENSRNOG000000048993	Metazoa_SRP	0.03	0.9881	-
MSTRG.28323.2	+∞	0.0492	Up	<i>cis</i>	ENSRNOG000000049584	AABR07070555.1	-0.13	0.8591	-
MSTRG.4080.13	+∞	0.0002	Up	<i>cis</i>	ENSRNOG000000049768	Adecy9	-0.04	0.7770	-
NONRATT025333.2	6.61	0.0000	Up	<i>cis</i>	ENSRNOG000000051719	AABR07065498.1	0.11	0.9304	-
NONRATT011312.2	+∞	0.0479	Up	<i>cis</i>	ENSRNOG000000051911	Rbp3	9.84	0.0000	Up
NONRATT024648.2	-∞	0.0492	Down	<i>cis</i>	ENSRNOG000000052540	SNORD113	0.45	0.6631	-
NONRATT005985.2	4.53	0.0490	Up	<i>cis</i>	ENSRNOG000000053047	Top2a	5.28	0.0000	Up
NONRATT016680.2	7.62	0.0041	Up	<i>cis</i>	ENSRNOG000000053081		3.59	0.0011	Up
NONRATT009382.2	8.35	0.0257	Up	<i>cis</i>	ENSRNOG000000056826	Arap2	0.21	0.6941	-
MSTRG.15263.2	-∞	0.0041	Down	<i>cis</i>	ENSRNOG000000060329	Emb	-0.06	0.7939	-
NONRATT015639.2	3.25	0.0005	Up	<i>cis</i>	ENSRNOG000000061058	Csde1	0.02	0.8739	-
NONRATT027585.2	7.19	0.0000	Up	<i>cis</i>	ENSRNOG000000061656	SNORD14	0.17	0.9160	-

lncRNA, long noncoding RNA; FC, fold change.

Table IV. Differentially expressed lncRNA mechanisms involved in *trans*-regulatory elements.

lncRNA ID	log2FC	Q value	Up/downregulated	Type	Gene name	log2FC	P-value	Up/downregulated
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ccl9	5.19	0.0017	Up
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Homer3	1.00	0.0611	-
ENSRNOT00000088402	+∞	0.0471	Up	Trans	Aurkb	2.35	0.0723	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Galns	1.03	0.0724	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Slc39a1	0.92	0.0739	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	AC099384.2	+∞	0.1052	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Hsd3b7	0.83	0.1369	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Klrlb1b	1.98	0.1413	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Me2	0.63	0.1558	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Pnma2	-0.51	0.1564	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Cass4	1.24	0.1599	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Klhl23	-0.44	0.2192	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Elac1	-0.49	0.2260	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Clef1	1.26	0.2519	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Fzd6	0.80	0.2590	-
NONRATT009960.2	4.06	0.0430	Up	Trans	Lcorl	-0.44	0.3199	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Gpr3711	0.40	0.3297	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Mmab	-0.35	0.3391	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Spon1	-0.28	0.3414	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ifngr2	0.44	0.3660	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Foxred2	-0.35	0.3732	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Prr22	-0.67	0.3889	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Sppl2a	0.40	0.3894	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Haus5	0.55	0.4019	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Cpvl	0.80	0.4041	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Fam120b	-0.24	0.4061	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Fbxo3	-0.21	0.4206	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ypel4	-0.24	0.4477	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Klhl26	-0.20	0.4480	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Sync	0.43	0.5076	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Lhfp15	-0.31	0.5231	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Mrpl52	0.44	0.5306	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Cldn15	-0.39	0.5315	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Mmps35	-0.18	0.5443	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Zfp382	-0.17	0.5640	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ube2k	-0.14	0.5697	-

Table IV. Continued.

lncRNA ID	log2FC	Q value	Up/downregulated	Type	Gene name	log2FC	P-value	Up/downregulated
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Drg1	-0.12	0.5755	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	P2rx5	-0.36	0.5770	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Xpnp3	0.25	0.5933	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	RGD1311345	0.28	0.5950	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Acer2	0.32	0.6034	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Urgcp	0.28	0.6182	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Megf8	-0.10	0.6223	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Lrtm2	-0.14	0.6301	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	RGD1562299	0.26	0.6325	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Rpl9	0.38	0.6347	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Slc25a44	-0.10	0.6348	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ssmem1	-0.28	0.6350	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Stt3a	0.24	0.6468	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Spire1	-0.09	0.6631	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	RGD1561777	-0.13	0.6846	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Luzp1	-0.09	0.6941	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Acot2	0.26	0.7000	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Fitm2	-0.07	0.7111	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Aox4	0.32	0.7374	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Golgal	-0.04	0.7775	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Lefty2	1.23	0.7977	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Zdhc24	-0.04	0.8075	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Zfp329	-0.03	0.8205	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Tmem101	-0.03	0.8236	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Dhh	0.28	0.8353	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ncr3	0.57	0.8354	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ppp1r15b	0.14	0.8423	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Zfyve27	-0.01	0.8439	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ints7	0.15	0.8457	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Dus1l	0.14	0.8545	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Ahsa2	0.15	0.8576	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Aif1l	0.15	0.8579	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Rsg1	0.16	0.8645	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Fuom	0.15	0.8883	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Cwfl9l1	0.12	0.8894	-
ENSRNOT00000092040	-3.35	0.0204	Down	Trans	Paqr7	0.01	0.8942	-

Table IV. Continued.

lncRNA ID	log2FC	Q value	Up/downregulated	Type	Gene name	log2FC	P-value	Up/downregulated
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Coa5	0.02	0.8985	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Cdc14b	0.13	0.8989	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Crebl2	-0.01	0.9081	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	RGD1564541	0.10	0.9210	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Slc15a1	-0.03	0.9211	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Ppm1k	0.03	0.9299	-
NONRATT025479.2	-4.14	0.0000	Down	Cis and trans	Gdf11	0.08	0.9402	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Fam20b	0.04	0.9436	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Anapc11	0.09	0.9536	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Tmem79	-0.04	0.9595	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Cwc25	0.06	0.9692	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Blvrb	0.07	0.9859	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Stk4	0.08	0.9880	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Rbm20	0.08	0.9896	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Tbc1d10b	0.06	0.9927	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Mapkbp1	0.07	0.9986	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Psmas8	1.00	1.0000	-
ENSRNOT000000092040	-3.35	0.0204	Down	Trans	Rbbp8nl	0.37	1.0000	-

lncRNA, long non-coding RNA; FC, fold change.




Figure 6. Validation of lncRNA RNA-seq data by RT-qPCR. Fold changes represent the comparison of the MCAO group with the control group. Blue bars indicate the fold change were detected with RNA-seq. ** $P < 0.01$ vs. the control group. The orange bars indicate the fold change detected using RT-qPCR. \$ $P < 0.05$ and \$\$ $P < 0.01$ vs. the control group. Comparison of the results obtained from RT-qPCR and RNA-seq revealed satisfactory consistency ($R^2 = 0.9338$). MCAO, Middle cerebral artery occlusion; lncRNA, long noncoding RNA; RNA-seq, RNA sequencing; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Metastasis associated lung adenocarcinoma transcript 1 was identified to have a function in ischemic stroke through inhibiting endothelial cell death and inflammation (36,37). Additionally, the upregulation of H19 imprinted maternally expressed transcript may induce apoptosis and necrosis in cerebral ischemic reperfusion injury (38-40). In the present study, a total of 77 upregulated and 57 downregulated DELs ($|\text{FC}| > 2$, $P < 0.05$) were identified through reliable RNA-seq and validated using RT-qPCR in an ischemic stroke group induced by MCAO compared with a control group.

HO-1-mediated neurogenesis has been demonstrated to be enhanced in ischemic stroke in mice (41). HO-1 has been revealed to promote angiogenesis following cerebral ischemic reperfusion injury in rats (42). GO enrichment analysis suggested that HO-1 was associated with responses to alkaloids, cellular responses to oxidative stress and responses to reactive oxygen species. BUB1B has been reported to promote tumor proliferation in glioblastoma (43,44). Similarly, BUB1B has been implicated in tumor growth and the progression of prostate cancer (45), and overexpressed BUB1B has been demonstrated to be involved in lung adenocarcinoma in humans (46). The KEGG enrichment analysis in the present study indicated that BUB1B was associated with the cell cycle. It has previously been reported that upregulated CCL2 is associated with protection from stroke induced by hypoxic preconditioning (47), and the knockdown of CCL2 was used to successfully reverse the drug resistance of tumor cells in gastric cancer (48). In the KEGG enrichment analysis performed in the present study, CCL2 was additionally associated with the cell cycle. Furthermore, based on the data presented in Fig. 3, HO-1, BUB1B and CCL2 may be regulated by a number of novel lncRNAs, including NONRATT008267.2, NONRATT015286.2, NONRATT004791.2, MSTRG.15067.2, NONRATT003289.2, NONRATT004566.2, NONRATT005985.2, NONRATT008198.2, NONRATT028439.2, NONRATT026753.2, NONRATT027268.2, MSTRG.15418.3, NONRATT016680.2, NONRATT015403.2,

MSTRG.29693.5, NONRATT009960.2, MSTRG.27670.3 and NONRATT000377.2. A previous study has suggested that the knockdown of DNA topoisomerase II α (Top2a) may suppress proliferation and invasion of colon cancer cells (49); based on the present regulatory analysis of DELs, Top2a, as a *cis*-regulatory gene of NONRATT005985.2, may have a vital function in ischemic stroke. Overall, the analyzed data provide novel DELs and an lncRNA-mRNA regulatory network that may provide a better understanding of ischemic stroke induced by MCAO.

Acknowledgements

The authors would like to thank Mr. Qiang Fan (Ao-Ji Bio-tech Co., Ltd., Shanghai, China) for help with data analysis.

Funding

The present study was financially supported by the National Key Research and Development Plan (grant nos. 2017YFC1701600 and 2017YFC1701601), the National Natural Science Foundation of China (grant nos. 81473387, 81503291 and 81703805), the Anhui Provincial Natural Science Foundation of China (grant no. 1508085QH191) and the Key Project of the National Science Fund of Anhui Province (grant no. KJ2013A169).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XD and DP conceived and designed the study. XD and QB performed the experiments. LH, CP, LX and HP analyzed the

data and drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by The Animal Experiments Ethics Committee of The Anhui University of Chinese Medicine (Hefei, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, *et al*: Heart disease and stroke statistics-2016 update: A report from the American Heart Association. *Circulation* 133: e38-e360, 2016.
- Tewari D, Majumdar D, Vallabhaneni S and Bera AK: Aspirin induces cell death by directly modulating mitochondrial voltage-dependent anion channel (VDAC). *Sci Rep* 7: 45184, 2017.
- Mitsios N, Gaffney J, Kumar P, Krupinski J, Kumar S and Slevin M: Pathophysiology of acute ischaemic stroke: An analysis of common signalling mechanisms and identification of new molecular targets. *Pathobiology* 73: 159-175, 2006.
- Deb P, Sharma S and Hassan KM: Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. *Pathophysiology* 17: 197-218, 2010.
- Dharap A, Bowen K, Place R, Li LC and Vemuganti R: Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome. *J Cereb Blood Flow Metab* 29: 675-687, 2009.
- Jeyaseelan K, Lim KY and Armugam A: MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. *Stroke* 39: 959-966, 2008.
- Dharap A, Nakka VP and Vemuganti R: Effect of focal ischemia on long noncoding RNAs. *Stroke* 43: 2800-2802, 2012.
- Zhao F, Qu Y, Liu J, Liu H, Zhang L, Feng Y, Wang H, Gan J, Lu R and Mu D: Microarray profiling and co-expression network analysis of lncRNAs and mRNAs in neonatal rats following hypoxic-ischemic brain damage. *Sci Rep* 5: 13850, 2015.
- Wei N, Xiao L, Xue R, Zhang D, Zhou J, Ren H, Guo S and Xu J: MicroRNA-9 mediates the cell apoptosis by targeting Bcl2l1 in ischemic stroke. *Mol Neurobiol* 53: 6809-6817, 2016.
- Xu Q, Deng F, Xing Z, Wu Z, Cen B, Xu S, Zhao Z, Nepomuceno R, Bhuiyan MI, Sun D, *et al*: Long non-coding RNA C2dat1 regulates CaMKII δ expression to promote neuronal survival through the NF- κ B signaling pathway following cerebral ischemia. *Cell Death Dis* 7: e2173, 2016.
- Qureshi IA and Mehler MF: Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. *Nat Rev Neurosci* 13: 528-541, 2012.
- Schaukowitch K and Kim TK: Emerging epigenetic mechanisms of long non-coding RNAs. *Neuroscience* 264: 25-38, 2014.
- Briggs JA, Wolvetang EJ, Mattick JS, Rinn JL and Barry G: Mechanisms of long non-coding RNAs in mammalian nervous system development, plasticity, disease, and evolution. *Neuron* 88: 861-877, 2015.
- Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? *Cell* 146: 353-358, 2011.
- Washietl S, Kellis M and Garber M: Evolutionary dynamics and tissue specificity of human long noncoding RNAs in six mammals. *Genome Res* 24: 616-628, 2014.
- Dharap A, Pokrzywa C and Vemuganti R: Increased binding of stroke-induced long non-coding RNAs to the transcriptional corepressors Sin3A and coREST. *ASN Neuro* 5: 283-289, 2013.
- Mehta SL, Kim T and Vemuganti R: Long noncoding RNA FosDT promotes ischemic brain injury by interacting with REST-associated chromatin-modifying proteins. *J Neurosci* 35: 16443-16449, 2015.
- Han L, Ji Z, Chen W, Yin D, Xu F, Li S, Chen F, Zhu G and Peng D: Protective effects of tao-Hong-si-wu decoction on memory impairment and hippocampal damage in animal model of vascular dementia. *Evid Based Complement Alternat Med* 2015: 195835, 2015.
- Duan X, Han L, Peng D, Chen W, Peng C, Xiao L and Bao Q: High throughput mRNA sequencing reveals potential therapeutic targets of Tao-Hong-Si-Wu decoction in experimental middle cerebral artery occlusion. *Front Pharmacol* 9: 1570, 2019.
- Pertea M, Kim D, Pertea GM, Leek JT and Salzberg SL: Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. *Nat Protoc* 11: 1650-1667, 2016.
- Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT and Salzberg SL: StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. *Nat Biotechnol* 33: 290-295, 2015.
- Sun L, Zhang Z, Bailey TL, Perkins AC, Tallack MR, Xu Z and Liu H: Prediction of novel long non-coding RNAs based on RNA-Seq data of mouse Klf1 knockout study. *BMC Bioinformatics* 13: 331, 2012.
- Kong L, Zhang Y, Ye ZQ, Liu XQ, Zhao SQ, Wei L and Gao G: CPC: Assess the protein-coding potential of transcripts using sequence features and support vector machine. *Nucleic Acids Res* 35 (Web Server Issue): W345-D349, 2007.
- Sun L, Luo H, Bu D, Zhao G, Yu K, Zhang C, Liu Y, Chen R and Zhao Y: Utilizing sequence intrinsic composition to classify protein-coding and long non-coding transcripts. *Nucleic Acids Res* 41: e166, 2013.
- Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Billis K, Cummins C, Gall A, Girón CG, *et al*: Ensembl 2018. *Nucleic Acids Res* 46 D: D754-D761, 2018.
- Knauss JL and Sun T: Regulatory mechanisms of long noncoding RNAs in vertebrate central nervous system development and function. *Neuroscience* 235: 200-214, 2013.
- Nikolayeva O and Robinson MD: edgeR for differential RNA-seq and ChIP-seq analysis: An application to stem cell biology. *Methods Mol Biol* 1150: 45-79, 2014.
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res* 13: 2498-2504, 2003.
- Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ: Basic local alignment search tool. *J Mol Biol* 215: 403-410, 1990.
- Tafer H and Hofacker IL: RNAplex: A fast tool for RNA-RNA interaction search. *Bioinformatics* 24: 2657-2663, 2008.
- Gene Ontology Consortium, Blake JA, Dolan M, Drabkin H, Hill DP, Li N, Sitnikov D, Bridges S, Burgess S, Buza T, *et al*: Gene ontology annotations and resources. *Nucleic Acids Res* 41 (Database Issue): D530-D535, 2013.
- Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 28: 27-30, 2000.
- Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. *Genome Biol* 4: P3, 2003.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
- Dykstra-Aiello C, Jickling GC, Ander BP, Shroff N, Zhan X, Liu D, Hull H, Orantia M, Stamova BS and Sharp FR: Altered expression of long noncoding RNAs in blood after ischemic stroke and proximity to putative stroke risk loci. *Stroke* 47: 2896-2903, 2016.
- Zhang J, Yuan L, Zhang X, Hamblin MH, Zhu T, Meng F, Li Y, Chen YE and Yin KJ: Altered long non-coding RNA transcriptomic profiles in brain microvascular endothelium after cerebral ischemia. *Exp Neurol* 277: 162-170, 2016.
- Zhang X, Tang X, Liu K, Hamblin MH and Yin KJ: Long noncoding RNA malat1 regulates cerebrovascular pathologies in ischemic stroke. *J Neurosci* 37: 1797-1806, 2017.
- Wang J, Cao B, Han D, Sun M and Feng J: Long non-coding RNA H19 induces cerebral ischemia reperfusion injury via activation of autophagy. *Aging Dis* 8: 71-84, 2017.

39. Tao H, Cao W, Yang JJ, Shi KH, Zhou X, Liu LP and Li J: Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis. *Cardiovasc Pathol* 25: 381-389, 2016.
40. Puyal J and Clarke PG: Targeting autophagy to prevent neonatal stroke damage. *Autophagy* 5: 1060-1061, 2009.
41. Nada SE, Tulsulkar J and Shah ZA: Heme oxygenase 1-mediated neurogenesis is enhanced by *Ginkgo biloba* (EGb 761®) after permanent ischemic stroke in mice. *Mol Neurobiol* 49: 945-956, 2014.
42. Dong B, Zhang Z, Xie K, Yang Y, Shi Y, Wang C and Yu Y: Hemopexin promotes angiogenesis via up-regulating HO-1 in rats after cerebral ischemia-reperfusion injury. *BMC Anesthesiol* 18: 2, 2018.
43. Ma Q, Liu Y, Shang L, Yu J and Qu Q: The FOXM1/BUB1B signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma. *Oncol Rep* 38: 3367-3375, 2017.
44. Lee E, Pain M, Wang H, Herman JA, Toledo CM, DeLuca JG, Yong RL, Paddison P and Zhu J: Sensitivity to BUB1B inhibition defines an alternative classification of glioblastoma. *Cancer Res* 77: 5518-5529, 2017.
45. Fu X, Chen G, Cai ZD, Wang C, Liu ZZ, Lin ZY, Wu YD, Liang YX, Han ZD, Liu JC and Zhong WD: Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. *Onco Targets Ther* 9: 2211-2220, 2016.
46. Chen H, Lee J, Kljavin NM, Haley B, Daemen A, Johnson L and Liang Y: Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinoma. *Genes Cancer* 6: 106-118, 2015.
47. Stowe AM, Wacker BK, Cravens PD, Perfater JL, Li MK, Hu R, Freie AB, Stüve O and Gidday JM: CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke. *J Neuroinflammation* 9: 33, 2012.
48. Xu W, Wei Q, Han M, Zhou B, Wang H, Zhang J, Wang Q, Sun J, Feng L, Wang S, *et al*: CCL2-SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer. *Int J Biol Sci* 14: 1054-1066, 2018.
49. Zhang R, Xu J, Zhao J and Bai JH: Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. *J Cell Biochem* 119: 7256-7263, 2018.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.